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This project consists of two chapters and revolves around PCL—TCP 
composite scaffolds.  
Pore size and porosity has always been an important property which 
affects cell and tissue infiltration. This has direct influence on bone 
regeneration and scaffold degradation upon implantation. In this study, 
acellular scaffolds of varying pore size and porosity were left in rabbit calvaria 
defects and explanted at 2, 4, 8, 12 and 24 weeks. Porosities (Group A: 74.9 ± 
1.7%, Group B: 86.7 ± 0.2%) and pore size (Group A: 500 ± 73µm, Group B: 723 
± 92µm) were determined through Micro CT. %BV/TV from Micro CT 
demonstrated an increase up to 8 week and stabilizes thereafter. Power law 
relationship governed scaffold degradation rate regardless of porosity. Group 
B scaffolds (6 weeks) reached 50% scaffold loss faster than Group A (10 
weeks). Mechanical properties between both groups were comparable 
throughout the study. Lastly, histology and histomorphometry detected bone 
formation and active vascularisation in all defects. In summary, porosities and 
pore size of PCL-TCP scaffolds has negligible effects on bone regeneration and 
scaffold degradation.  
Chapter 4 focused on the effects of BMP-2 and heparin on pig 
osteoblasts. Porcine osteoblasts obtained through explant culture displayed 
highest ALP activity in the presence of 100ng/ml of BMP-2 and 300ng/ml of 
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heparin. Alizarin red staining and western blot confirmed the bioactivity of 
BMP-2 used. Protein release from Group D scaffolds has a biphasic release 
similar to Group B. This is in agreement with BMP-2 release profile. ALP 
activities of various groups were comparable mainly due to low concentration 
of eluted BMP-2. In conclusion, heparin and BMP-2 has demonstrated its 
potential as co delivery system in this preliminary study. More studies should 
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CHAPTER 1: INTRODUCTION 
 
1.1 BACKGROUND 
This chapter aims to give the reader an overview of the current trends in 
bone tissue engineering (BTE). Following that, limitations of available 
treatments for bone defects and various strategies of BTE will be discussed.  
 
1.1.1 Current trends in BTE 
Healthcare spending in US can be represented by National Health 
Expenditure (NHE). It is defined as the “total amount spent to purchase 
healthcare goods and services as well as investment in the medical sector to 
produce healthcare services”(NHED, 2006). NHE has been rising rapidly 
throughout the years from $153 billion in 1976 to $1990 billion in 2006 (NHED, 
2006). Healthcare comprises of 16% of GDP in 2006 and is expected to increase 
to 19% in a decade. Average annual growth of healthcare expenses involving 
musculoskeletal conditions is ranked second at 8.5% (HCUP, 2006). The huge 
growth can be attributed to the rapidly aging population. Also, more high-
impact accidents have led to an increase in serious limb trauma. Bone and Joint 
decade (2000-2010) was set up by United Nations and World Health 
Organisation to raise awareness of the growing costs and also to deepen 
understanding of musculoskeletal diseases through research (BJD, 2000-2010). 
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In Singapore, Government Health Expenditure/Total Government Expenditure 
increased from 6.5 to 7.1% between 2006 to 2008 (MOH, 2008). 
 
1.1.2 Limitations of current treatments for bone defects 
For surgical procedures involving bone grafts, patients usually suffer 
from trauma-related injuries or bone fractures. Currently, the gold standard 
for bone grafts is autologous bone commonly taken from iliac crest. 
Autologous bone are bones extracted from another part of patient’s own body 
(Casey K C, 2006). The drawbacks include an additional surgery site for 
harvesting and limited availability (Enneking et al., 1980). Other types of bone 
grafts include tissues taken from human donors (allografts) or xenografts 
obtained from animals. Allografts are not as popular due to the increased risk 
of disease transmission, high cost, graft rejection (Gitelis and Saiz, 2002),  and 
the acceptance of xenografts in certain races or religion may be highly 
controversial due to its animal origin. Allografts which have undergone 
chemical treatment to remove minerals are known as demineralised bone 
matrix. Collagen and other growth factors are still being retained but they 
have low mechanical strength due to loss of minerals. Even though it is widely 
used as bone substitute, its effectiveness fluctuates in different patients 
(Drosos et al., 2007; Kay, 2007). Large clinical defects resulting from bone 
cancer or trauma are currently treated with titanium plates. This may lead to 
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complications like rejection and stress shielding. In serious cases, revision 
surgery has to be conducted to replace the implant. oLimitations to current 
bone grafts as discussed propel researchers to look into the field of bone tissue 
engineering for an ideal bone substitute.  
 
1.1.3 Strategies in BTE 
Tissue engineering is the restoration, improvement, maintenance and 
substitution of damaged tissues and organs using principles of biology and 
engineering (Langer and Vacanti, 1993). BTE consists of an interplay of 
scaffold technology, growth factors and cells. In this thesis, the focus will be on 
using composite scaffold technology in enhancing bone regeneration through 
in vitro and in vivo studies.  
Scaffold intended for BTE should possess the following properties:   
1. High porosity and pore interconnectivity to allow cell growth, 
migration and promote vascularisation (Sundelacruz and Kaplan, 2009). 
2. Biocompatible, bioresorbable and controllable degradation rate to 
match surrounding tissue growth.  
3. Suitable surface topography whereby cells are able to attach, proliferate 
and differentiate (Stevens et al., 2008).  
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4. Mechanical properties that closely resemble the defect site and has the 
strength to withstand load upon implantation (Hutmacher D.W, 2001).  
5. The ability to impregnate cells, growth factors and drugs which can 
trigger surrounding cells for bone regeneration; controlled drug or 
growth factor delivery can also be effectively targeted at the defect site.  
6. Ease of manufacturing is necessary for the scaffold to be mass 
produced.  
7. Customizability of the shape and size of scaffold will be favourable for 
use in different clinical applications (Jones, 2005).  
It must be noted that interdependent relationships exist among the desired 
properties discussed above. One example is when the porosity of scaffold is 
increased, cells are able to infiltrate easily but mechanical strength will 
decrease. Scaffold degradation time will also shorten due to lower scaffold 
volume. This particular scaffold may be suitable for non load bearing 
anatomical sites but not for the reverse.   
In this study, PCL-TCP composites were selected as the delivery 
vehicle. Hydrophobic nature of PCL is improved by adding bioactive TCP 
particles. Mechanical strength of composite is increased as TCP scaffolds are 
originally brittle. Furthermore, PCL-TCP composites have shown to be 
biocompatible, controlled degradation rate and effective delivery systems for 
growth factors (Rai et al., 2005b; Yeo et al., 2008a). 
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Growth factors are “secreted by a wide range of cell types to transmit 
signals that activate specific developmental programs controlling cell 
migration, differentiation and proliferation” (Chen and Mooney, 2003). They 
transmit signals by attaching onto receptors on the cell surface. Signals will 
then be passed through the cell membrane and results in the expression of a 
target gene. This process is extremely complex and may involve multiple 
growth factors and receptors for one particular signal (Johnson et al., 1988; 
Pimentel, 1994). Some of the highly researched osteoinductive growth factors 
include Bone morphogenetic proteins (BMP-2), Transforming growth factor-β 
(TGF-β), Fibroblast growth factor (FGF), Insulin-like growth factor (IGF) and 
Platelet-derived growth factor (PDGF). BMP-2 is arguably the most potent 
osteoinductive growth factor and will be elaborated on in the next chapter 
(Bessa et al., 2008b). FGF stimulates neo-angiogenesis, indirectly augmenting 
bone regeneration by providing necessary nutrients to the core of defect site 
(Hurley et al., 1993; Rifkin and Moscatelli, 1989). IGF enhances the proliferation 
of osteoblasts ,osteoclasts and mineralisation (Khan et al., 2000). PDGF exhibits 
stimulatory effects on osteoblasts proliferation (Canalis et al., 1989) especially 
in bone fracture healing (Andrew et al., 1995). 
Drug delivery system (DDS) is a “technology that enables biological 
signalling molecules to enhance in vivo therapeutic efficacy by combination 
with biomaterials”(Tabata, 2005). Growth factors cannot be applied to the 
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defect site in solution because they will immediately diffuse away from the 
defect site. In addition, direct injection of growth factors at high doses has been 
shown to generate undesirable results (Yancopoulos et al., 2000). Negative 
feedback at high levels has been shown to induce heterotopic bone formation 
(Paramore et al., 1999) and even resulted in formation of antibodies in clinical 
trials (Walker and Wright, 2002). Here, a carrier is needed to ensure sustained 
delivery of a growth factor at the defect site. The release profile of the growth 
factor from the vehicle shall usually be gradual and controllable spatially and 
temporally to ensure maximum therapeutic effects (Chen and Mooney, 2003).  
 
1.2 RESEARCH OBJECTIVES 
The general aim in this thesis was to evaluate and improve on the current 
properties of PCL-TCP composites from various aspects namely porosity and 
cell modulators in both in vitro and in vivo environments.  
The two specific aims of this research was 
1. To investigate the effects of bone regeneration, scaffold degradation and 
mechanical properties of PCL-TCP scaffolds with different porosities in 
vivo. 
2. To evaluate the effects of heparin on BMP-2 release and bioactivity from 
PCL-TCP scaffolds in vitro.  
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1.3 RESEARCH SCOPE 
In the first chapter, two different groups of scaffolds were randomly placed in 
rabbit calvaria defects and sacrificed after 2, 4, 8, 12 and 24 weeks. [Group A: 
~75% porosity, Group B: ~82% porosity]. Upon sacrifice, at each interval, the 
specimens were subjected to µ-CT analysis, mechanical test and 
histomorphometric analysis. This will enable us to determine the effects of 
porosity differences on bone regeneration, scaffold degradation and 
mechanical integrity.  
The final chapter firstly examined the effectiveness of BMP-2 and heparin 
on pig osteoblasts in enhancing osteoblast differentiation. Pig osteoblasts was 
chosen to simulate implantation conditions which is in line with our future 
plan to assess the co-delivery system in a porcine model. Optimal 
concentration of both BMP-2 and heparin was then determined and adapted 
for subsequent analysis. Release profile of BMP-2 from PCL-TCP scaffolds was 
plotted for signs of sustained delivery when immersed in PBS solution. 
Heparin was chosen to improve binding and regulate release of BMP-2 here 







CHAPTER 2: LITERATURE REVIEW 
 
2.1 BONE PHYSIOLOGY 
In order to regenerate bone using BTE techniques, the understanding of the 
structure and cells which participate in bone repair is of utmost importance. 
Bone is composed of around 70-90% of minerals with the rest in the form of 
proteins. Within the proteins in bone, the ratio of collagenous to non-
collagenous stands at 9:1. This is in stark contrast with other tissues consisting 
of only 10% collagenous proteins (Gokhale et al., 2001). High strength and 
rigidity of the bone stem is attributed to its mineral component, which is 
similar to hydroxyapatite (Ca10(PO4)(OH)2). Bone has an elastic nature and it is 
also resistant to tension due to the high amount of collagen fibres.  
In Figure 2.1, there are two layers of bone namely: cortical (compact) and 
trabecular (spongy) bone. Cortical bone surrounds the outer layer of bone with 
thick and compact walls. It houses the medullary cavity where bone marrow 
resides during life. Trabecular bone, which has a spongy honeycomb structure, 
is only located at the epiphysis ends of long bone. Haematopoietic bone 
marrow also resides within the pores of trabecular network. With the 
exception of the articulating surfaces, the cortical bone is surrounded by the 
periosteum which is a thin layer of connective tissue made of a collagen rich 




Figure 2.3: Diagram showing skeletal long bone structure which comprises of 
cortical and trabecular bone (Biomedical Tissue Research Group, 1996)  
There are a wide variety of cells that participate in the bone remodelling 
and regeneration process (Figure 2.2).  The main duty of osteoclasts is to 
remove and resorb bone. When osteoclasts determine a bone site to be 
resorbed, it will create a barrier on its surface using its apical membrane. The 
pH level beneath osteoclast will be decreased, which triggers the formation of 
hydrogen ions and lysomal enzymes. After the resorption phase, Howship’s 
lacuna, which is a depression with ruffled border, is created (Raisz and 




Figure 2.4: Schematic diagram showing stages of bone remodelling process 
(Biomedical Tissue Research Group, 2007) 
In the renewal phase, macrophages are present at resorbed site. 
Osteoblasts, which had the ability to synthesis new bone, will continue to 
mineralise. During this process, it maintains and develops various channels 
with surrounding cells to facilitate various cellular actions through receptors 
and transmembrane proteins. When osteoblasts have completed the bone 
formation process, it will experience multiple transformations. It can convert 
itself into bone lining cells, which cover bone surfaces after quinesence phase. 
Some osteoblasts may be programmed to die after fulfilling its duties. The rest 
will become osteocytes and reside in bone matrix. Osteocytes are classified as 








2.2.1 Polycaprolactone (PCL) 
Poly(ε-caprolactone) (PCL)  is a semi crystalline resorbable polyester.  
PCL belong to aliphatic polyester family and thus share similar properties 
with other members such as polyglycolide (PGA) and polylactide (PLA). It has 
a low melting point of between 59 to 64°C, depending on its level of 
crystallinity. Low melting temperature enhances its processibility. It has a low 
glass transition temperature of around -60°C which explains its ductile and 
rubbery state at room temperature (Juan Pena, 2006). 
PCL has a higher decomposition temperature (350°C) relative to other 
aliphatic polyesters which will decompose between 235°C and 255°C. PCL also 
possess favorable mechanical properties: Elastic modulus between 300 to 
400MPa which matches the stiffness of cancellous bone (100 – 300MPa) and a 
tensile strength which ranges from 15 to 60MPa (Zein I, 2002).  
 
Figure 2.3: Chemical Structure of PCL polymer (Wikipedia, 2006) 
Each monomer of PCL consists of five methylene groups and one ester group. 
PCL is hydrophobic due to the presence of non polar methylene groups 
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(Figure 2.3). Aliphatic ester linkage in PCL makes it susceptible to hydrolytic 
degradation.  
Low glass transition temperature contributes to the high permeability of 
PCL. It is this property that allows PCL to form copolymer blends with other 
polymers. PCL is widely used in its copolymer state in controlled release drug 
delivery applications (James M Pachence, 2000). PCL is an FDA approved 
material used widely in biomedical applications eg in sutures (Rezwan K, 
2006).  
2.2.2 Biodegradation 
The degradation mechanism of polymers used for bone tissue 
regeneration must be elucidated thoroughly before the product can be released 
into the market. The degradation profile of the scaffold will have a significant 
effect on the mechanical properties and various cellular activities that include 
host tissue response (Y. Lei, 2007). If the scaffold degrades well before 
sufficient bone regeneration take place, implant failure may result. Conversely, 
if the scaffold fails to degrade fast enough, it will act as a barrier and hinder 
new bone formation. PCL degrades completely in vitro and vivo to release 
harmless by-products. This is one advantage that PCL possess which make it 
highly suitable for use in medical devices. Unlike PCL, PLGA degrades upon 
implantation to form acidic byproducts which is toxic to the body and will 
affect cell growth and proliferation directly (Hak-Joon Sung, 2004). 
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The process of polymer degradation at different pH has been 
scrutinized by Burkersrodaa et al. The study concluded that polymer can 
either break down by surface erosion or bulk degradation. The mechanism of 
degradation is dependent on three factors: 1. size of matrix, 2. water diffusivity 
into scaffold centre, 3. rate of degradation of polymer reactive groups 
(A.S.Htay, 2004; Friederike von Burkersrodaa, 2002). PCL follows a two step 
degradation process when it is placed in an in vivo environment. The first step 
is a non-enzymatic, random hydrolytic ester cleavage which is triggered 
automatically by carboxyl end groups of the polymer chain. Chemical 
structure and molecular weight of polymer will affect the duration of the first 
step of degradation. When the molecular weight of polymer decreases to about 
5000, second step of degradation will commence. The rate of chain scission and 
weight of polymer decreases as a result of the formation and removal of short 
chains of oligomers from the scaffold matrix. Fragmentation of polymer 
precedes the absorption and digestion of polymer particles by phagocytes or 








2.2.3 Tri-Calcium Phosphate (TCP) 
 
Figure 2.4: Chemical structure of tricalcium phosphate (CambridgeSoft 
Corporation, 2004) 
TCP is a biocompatible and biodegradable material used widely and 
successfully for bone replacement for many years. Some forms of calcium 
phosphates include: mono-, di- and tetra calcium phosphate, hydroxyapatite 
and β-whitlockie. The ideal Ca/P ratio is 1.6, which is similar to 
hydroxyapatite. The higher the Ca/P ratio, the more stable the compound will 
be in solutions (Lakes, 2007). TCP is found naturally in the inorganic phase of 
bone in form of hydroxyapatite. TCP is also responsible for the hardness of 
bone, dentine and enamel. TCP exhibit excellent regenerative activity when 
placed in vivo (Beruto et al., 2000). However, it has poor mechanical properties 
such as low compressive strength. This contributed to its brittleness when 
fabricated in blocks and scaffolds (K A Hing, 1998).  
 
2.2.4 PCL-TCP scaffolds 
The purpose of using composites for medical applications usually is to 
reduce drawbacks of individual materials and the benefits of both are 
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combined together. Here, PCL is highly hydrophobic which leads to a longer 
degradation period (>2 years) in vitro and in vivo. TCP alone, when fabricated 
into a scaffold is brittle and weak in strength. By using PCL-TCP scaffolds for 
guided bone regeneration, the above disadvantages will be minimized. 
Previous research has showed that adding TCP to PCL by physically blending 
to produce composite scaffold, the degradation rate of PCL can be accelerated. 
In particular, under accelerated hydrolytic conditions of 5M NaOH, PCL-TCP 
scaffolds completely degrades at 48 hrs where PCL scaffolds require 6 weeks 
for degradation to complete (Christopher XF Lam, 2007). Our research team 
found that PCL-TCP scaffolds degrade to 40% by weight when it was 
immersed in standard culture media after six months. Recalling that the 
optimal degradation rate of scaffolds intended for dentoalveolar defects is 
about five to six months, the need for accelerated degradation propels our 
team to look into the possibility of alkaline and enzymatic degradation (Yeo et 
al., 2008a). 3M NaOH produced a more favourable surface morphology for 
bone regeneration relative to lipase treated PCL-TCP scaffolds. Alkaline 
treated scaffolds have a slower and more predictable degradation profile; 
whereas lipase treated ones have lower mechanical properties at each 
treatment point (Yeo et al., 2008b).   
Selective surface modification can be used to improve the surface 
hydrophilicity and pore morphology of biodegradable polyester scaffolds 
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without affecting the core of the rods. It was reported that cellular adhesion 
and proliferation are closely dependent on the topographical nature of the 
biomaterial surface (Boyan BD, 1995). An increase in surface area or roughness 
of scaffold matrices enhanced osteoblast response, which lead to improved 
osteoconductivity (Brett PM, 2004; Price RL, 2004). We showed that after 
NaOH treatment, surface wettability of PCL-TCP scaffolds increased 
significantly but the overall pore dimensions and honeycomb structure 
remains unaffected. Scaffolds subjected to longer alkaline treatments exhibited 
larger and deeper micro pits sizes, thus increasing the surface area to volume 
ratio favourable for better cell adhesion and bone growth (Yeo et al., 2010).  
PCL-TCP scaffolds had also been investigated as a delivery vehicle for 
BMP-2. In the novel DDS, fibrin sealant and BMP-2 were loaded onto PCL-
TCP scaffolds and their elution profile and bioactivity in different stages were 
analysed. Even though loading efficiency of PCL-TCP scaffolds stood at 43%, 
they were more uniformly distributed as compared with PCL scaffolds. PCL-
TCP scaffolds when loaded with 20µg/ml exhibit a triphasic release profile 
which had a delayed release profile than PCL scaffolds. BMP-2 also retained 
its bioactivity upon release at all time points (Rai et al., 2007; Rai et al., 2005b).  
PCL-TCP scaffolds have also proved to be a suitable delivery system for 
platelet-rich plasma as demonstrated by its sustained release in PBS and 
simulated body fluid (Rai et al., 2007).  
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2.2.5 Bone Morphogenetic Proteins (BMP-2) 
It has been discovered a century ago that bone has excellent regenerative 
capabilities. Ectopic bone formation was induced using decalcified bone or 
injected bone extracts in one of the earliest study on bone regeneration (Senn, 
1889). The breakthrough came about when Marshall Urist discovered that 
bone formed at ectopic sites in rodents upon addition of proteins extracted 
from demineralised bone matrix. He named the protein “Bone Morphogenetic 
Proteins (BMP)” as its regenerative capability closely matched inherent bone 
repair process (Urist, 1965).  
BMP consists of a long hydrophobic stretch between 50-100 amino acids in 
length. BMP-2, prior to cell secretion, is made up of signal peptide, pro-
domain and mature peptide. Upon secretion, the signal peptide is cleaved 
(Xiao et al., 2007). BMP-2 belongs to the superfamily of transforming growth 
factor (TGF)-β. Members in the family mainly have roles in bone and cartilage 
development. Some other functions of BMPs include heart development 
(Callis et al., 2005; Simic and Vukicevic, 2005) and kidney formation (Simic and 
Vukicevic, 2005). There exists a heparin binding site in N-terminal region of 
mature BMP-2 polypeptide. In pioneering work by Ruppert in 1996, it was 
shown that BMP-2 activity was increased upon interactions with heparins 
present in ECM. In the presence of N terminus of BMP-2 and heparin, there is 
a five-fold increased in bioactivity (Ruppert et al., 1996). This lead to various 
studies on heparin effects on BMP-2 in mind of effective bone regeneration.  
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BMP signalling is important for morphogenesis to occur at a cellular level 
initially. There are two types of receptors: BMPR-1 and BMPR-2. Both have to 
work together for the signalling process.  After BMP has bound itself strongly 
to the heteromeric complex of receptors, Smads proteins are activated 
instantaneously.  Smads are nuclear effector proteins that are part of signalling 
pathway in BMP signalling cascades. There are three different groups of 
Smads:  Common mediated Smads (C-Smads) – Smad 4, Receptor regulated 
Smads (R-Smads) – Smad 1, 5, 8 and inhibitory Smads (I-Smads) – Smad 6 and 
7. In Figure 2.5, following the adhesion of BMP-2 to BMPR-1 receptor, 
phosphylation of R-Smads will be follow. Phosphylated R-smads will form 
heteromeric complex with Smad 4 and be translocated into the nucleus. 
Transcription of target gene occurs in the presence of transcription factors and 
heteromeric complex. Signalling is regulated by inhibitory Smad 6/7 




Figure 2.5: Activation of SMAD proteins after BMP mediation (Sakou, 1998) 
However, BMP-2 has several disadvantages. It degrades rapidly in vivo 
(Yamamoto et al., 2003). Excessive dosages of BMP-2 were shown to trigger 
bone formation away from defect site (Valentin-Opran et al., 2002). 
Furthermore, subsequent administrations of BMP-2 will be costly. Hence, for 
BMP-2 to function effectively in treatment of bone defects, more need to be 
done in the following areas (Bessa et al., 2008a): 
1. Optimised variables for clinical translation.  
2. Good carrier biocompatibility and biodegradability. 
3. Efficient BMP-2 loading method. 
4.  Sustained released targeted at defect site. 




The discovery of heparin occurred in John Hopkins University in 1916.  
While researching on the cause of blood clotting, Jay McLean accidentally 
collected substances that inhibit clotting. It was named heparin thereafter. 
Following this discovery, more efforts were targeted at understanding the 
structure of heparin. The first commercialisation of bovine lung and porcine 
intestinal heparin was carried out in Toronto and Stockholm.  
 
Figure 2.6: Chemical structure of Heparin (Gray et al., 2008) 
Heparin is a sulphated polysaccharide which belongs to 
glycosaminoglycan (GAG) family (Figure 2.6). They are linear 
heteropolysaccharides that alternates between glucosamine and iduronic acid 
(Lever and Page, 2002). It is one of the most negatively charged molecules 
relative to its small size. Sulfates and carboxylates groups contributed to the 
high net negative charge (Caughey, 2003). Size of low molecular weight 
heparin used in this study varies from 2-10kD. Heparin is mainly found in 
mast or granulated cells in various organs. Heparin is also widely used as an 
anticoagulant in the treatment of stroke and coronary artery disease.  
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There are heparin binding sites in some growth factors which played an 
important role in their modulation of cell activities. It has been shown that 
heparin binds strongly to proteins with highly positive-charged binding sites. 
However, heparin sulphates favoured sites where basic residues are far apart 
from each other (Fromm et al., 1997). Aside from the usual ionic bonding, 
heparin also interacts with proteins through hydrogen bonding and 
hydrophobic forces (Bae et al., 1994). Heparin and heparan sulphates are 
structurally 70% similar to each other. Heparan sulphates are less sulphated 
and thus have a lower overall negative charge than heparin. Even though they 
are made up of same units, heparan sulphates have a higher glucosamine and 
lower iduronic acid component (Lever and Page, 2002). Despite the 
differences, heparin has been used widely as a model for the costly heparan 
sulphate.  
Heparin has been demonstrated to possess binding affinities for growth 
factors including VEGF and BMP-2 (Ruppert et al., 1996). As a result, heparin 
has been incorporated into biomaterials for the purpose of binding to 
endogenous growth factors (Nillesen et al., 2007; Steffens et al., 2004). Heparin 
has been shown previously to enhance osteoblast differentiation through BMP-
2 activity in vitro (Ruppert et al., 1996). In a recent study, it was reported that 
heparin prolonged BMP-2 degradation by 20-folds in culture medium. In 
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addition, higher bone mineral density was observed in subcutaneous implants 



















CHAPTER 3: EFFECTS OF POROSITIES OF PCL-TCP 
SCAFFOLDS ON BONE REGENERATION, SCAFFOLD 
DEGRADATION AND MECHANICAL PROPERTIES. 
 
3.1 INTRODUCTION 
As highlighted in chapter 1, shortcomings of current bone grafts motivate 
researchers to look into polymeric scaffolds for better substitutes. Important 
characteristics for a scaffold to function effectively as bone void filler at defect 
sites include:  1) Highly porous and well connected pores to facilitate cellular 
and vascular infiltration. 2) Biodegradable and predictable degradation profile 
which coincides with surrounding tissue growth. 3) Surface characteristics that 
allows for greater osteoblast attachment and function. 4) Mechanical 
properties that is similar to defect site and is able to withstand load right after 
implantation. 5) Easy loading of cells and proteins that are able to induce bone 
regeneration. (Hutmacher et al., 2001; Jones, 2005; Temenoff and Mikos, 2000). 
In this chapter, we will focus on the porosity of scaffold. Pores are a 
necessary feature in scaffolds as they allow for cellular migration and 
proliferation. Porosity of a scaffold is defined as the ratio of voids to the 
overall volume occupied by the scaffold. Porosity and pore size of a scaffold 
are closely interrelated with each other. Scaffolds with higher porosity will 
have larger pore size provided that they remained constant throughout. These 
are structural properties of scaffolds which is independent of the material. In 
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addition, it determines the flow of nutrients and metabolic wastes through the 
scaffold (Kuboki et al., 1998).  
Optimal pore size has always been highly debated amongst researchers. A 
wide range of pore sizes from 10 – 600 µm have been tested in BTE with 
porosities from 43 to 87.5% (El-Ghannam, 2004; Lickorish et al., 2004; Roy et 
al., 2003; Zhang and Zhang, 2002). New bone growth was observed in all 
defects in above studies. Noteworthy, scaffolds with engineered channels 
exhibited larger new bone area compared to non porous ones and those that 
were left unfilled (Roy et al., 2003).  It has been previously shown that direct 
osteogenesis was seen in pore sizes larger than ~300µm due to increased 
vascularisation. Conversely, osteochondral ossification was facilitated when 
pore size falls below 300µm (Gotz et al., 2004; Karageorgiou and Kaplan, 2005; 
Kuboki et al., 2001; Tsuruga et al., 1997). Thus, it can be seen that porosity and 
pore size has a great influence on the bone regeneration mechanism at bone 
defects.   
PCL-TCP scaffolds fabricated by Fused Deposition Modelling (FDM) have 
a unique and consistent architecture. PCL-TCP scaffolds used in this study 
have a 0/60/120° lay-down pattern. Angles here are with respect to the first 
layer and parallel to polymer rods spaced evenly apart from each other. At the 
forth layer, the pattern repeats itself to produce scaffold with triangular pores 
when viewed from above. A regular distribution of pores is visible from the 
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side. By changing FDM parameters, scaffolds of different porosity and pore 
size can be customised.  Fully interconnected pores and porosity of 65% 
allowed canine osteoblasts to attach and proliferate on PCL-TCP scaffolds (Rai 
et al., 2004). Combination with platelet-rich plasma in dog mandible 
demonstrated higher bone regeneration and similar scaffold degradation 
relative to controls (Rai et al., 2007; Rai et al., 2005a; Rai et al., 2005b). Previous 
analysis by our group showed that surface modification with alkaline 
treatment created micropores on rods of scaffolds and increases its surface 
roughness concurrently. However, its mechanical properties were not 
compromised; instead increased bone growth was observed within surface 
modified scaffolds upon implantation (Yeo et al., 2008b; Yeo et al., 2009a, 
2010).  
The purpose of this study was to evaluate the effects of varying porosities 
of PCL-TCP scaffolds on bone regeneration, scaffold degradation and 
mechanical properties in a rabbit calvarial model. Compressive and shear 
strength of scaffolds were obtained through mechanical testing. Micro CT and 
histomorphometry analyses provided us with information on scaffold 
degradation and bone ingrowth. Histology was used to examine scaffold-





3.2 MATERIALS AND METHODS 
3.2.1 Scaffold Fabrication 
Scaffold specimens (Osteopore International Pte Ltd, Singapore) were 
fabricated with PCL- 20% TCP filaments using a fused deposition modeling 
(FDM) 3D Modeler RP system from Stratasys Inc (Eden Prairie, MN). Blocks of 
50 x 50 x 2mm were created directly in Stratasys Quickslice (QS) software. A 
lay-down pattern of 0/60/120o was used to give a honey-combed like pattern of 
triangular pores. The specimens were cut into smaller discs of 6mm in 
diameter and 2mm in thickness subsequently. PCL-TCP scaffolds were 
immersed in ethanol for sterilisation. This was followed by rinsing 3x in 
phosphate buffer saline (PBS, 137 mM NaCl, 2.7 mM KCL, 10 mM Na2HPO4, 
1.8 mM KH2PO4
3.2.2 Porosity Calculation 
, pH 7.4). Scaffolds were dried overnight prior to 
implantation. 
Porosities were calculated by first measuring the weight and volume of 
each sample. Apparent density of the scaffolds was calculated using the 
following formula: ρ * = m (g) / V (cm3). Finally, scaffold porosities = ε = 1- ρ * / 
ρ x 100 % (ρ = 1.17 g/cm3
3.2.3 Experimental Design 
) were obtained. 
The scaffolds were randomly assigned to the defects made in the 
calvaria of rabbits and followed up for 2, 4, 8, 12 and 24 weeks.  
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Two groups of PCL-TCP scaffolds (Figure 3.1) were analysed: 
Group A: ~75% porosity 
Group B: ~85% porosity 
  
Figure 3.1: Micro CT images of scaffolds before implantation (A) Group A (B) 
Group B 
 
Micro-CT, mechanical strength testing (compressive strength and push 
out test), histology and histomorphometric analyses were performed. A 
minimum of 12 samples were required for each experimental group at 2, 4, 8, 
12 and 24 weeks to have sufficient data for analysis as recommended by ISO 
standard 10993-6. Since we had a total of 24 samples at each time point and 2 
samples were implanted in each rabbit, 60 rabbits were needed for the entire 
study. 
3.2.4 Animal husbandry and scaffold implantation 
Sixty, 6-8 month old New Zealand White male rabbits were used. The 
study was approved by the SingHealth Institutional Animal Care and Use 
Committee (IACUC) and conformed to the respective guidelines. The rabbits 
B A 
1 mm 1 mm 
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were operated on under general anesthesia, which consisted of an 
intraperitoneal injection of ketamine and xylazine mixture (75 mg/ kg + 10 mg/ 
kg). Under anesthesia, the skull region of the rabbit was shaved and scrubbed 
with iodine, followed by disinfection with 70 % ethyl alcohol.  
A midline incision was made in the skin of the calvaria along the 
sagittal suture line. The soft tissue and periosteum are elevated and reflected. 
Under constant saline irrigation, 6 mm diameter circular and 2 mm deep 
defects were made using the appropriate trephine drills. A total of 2 circular 
defects were made on the calvarium of each rabbit. Care is taken to preserve 
the dura. Defects were randomly assigned to receive 1 of the 2 test scaffolds 
(Figure 3.2). Prior closure, a non-resorbable membrane was positioned over the 
defects to prevent soft tissue ingrowth. This was followed by repositioning of 
the periosteum to cover the scaffolds followed by closure of the skin with 
sutures. The rabbits were then given carpofen (1-2 mg/ kg) and cephalexin (15-
20 mg/ kg) subcutaneously for 3 and 5 days respectively. 
 
Figure 3.2: Implantation of scaffolds into rabbit calvarial defects 
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Twelve rabbits were euthanized at 2, 4, 8, 12 and 24 weeks respectively. 
All samples were processed and analyzed accordingly. The tissues 
surrounding the selected implanted scaffolds were carefully removed and 
stored in 10 % neutral buffered formalin (NBF) for histology (n = 3). The 
remaining samples were wrapped in PBS-soaked gauze and frozen at -20 ºC 
and subsequently subjected for micro-CT (n = 4; non-destructive), push out (n 
= 4), compressive strength testing (n = 4) analyses. The rabbits were closely 
monitored everyday for the first week for presence of swelling, pain and 
infection.  They were then observed weekly for severe weight loss (20-25 %) 
and any other complications. 
3.2.5 Micro-CT analysis 
PCL-TCP scaffolds were scanned isotropically at 14 µm resolution with 
an SMX-100CT micro-CT scanner (Shimadzu, Japan) using a cone CT scanning 
technique. To ensure a consistent CT image resolution among all the datasets, 
the scanner turntable location was fixed at a specific source-to-object distance 
(SOD; 48.03 mm) and source-to-image distance (SID; 361.30 mm) respectively. 
X-ray parameters were set at 33 kV and 156 µA and the CT images were 
processed at a scaling coefficient of 100 and averaged 3 times. Region of 
interest (6 mm diameter) was drawn at the site of implantation. Resultant 
micro-CT datasets for each bone cube were evaluated for microarchitectural 
parameters using VG Studio Max software (Heidelberg, Germany). Overall 
bone formation and scaffold volume loss were obtained and analyzed. 
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3.2.6 Mechanical strength testing 
Compressive test 
Two kinds of mechanical testing (compressive test and push out test) 
were performed using the Instron 5500 micro tester (Instron, Canton, MA) 
with a 1kN load cell. Each specimen was placed between 2 flat plates for 
compression testing. The scaffolds were compressed at a speed of 1mm/ min 
up to 80% of scaffold original thickness at room temperature. The mechanical 
results of load and extension were used to calculate the σ, Compressive Stress 
(MPa) = [Load (N) / Area (m2)] x (1 x 10-6
Utilizing a similar Instron 5500 micro tester, push out test was done 
using the same configuration except that a support jig with a hole of 7.2 mm 
was used. Schematic diagram was shown previously (Yeo et al., 2009a). 
Interfacial shear strength between old bone and the newly regenerated bone-
scaffold composite was calculated by dividing peak force with cross sectional 
area of specimen.  
); ε, Strain = Extension (mm) / Original 
Length (mm); and E, Elastic Modulus (MPa) = Compressive Stress (MPa) / 
Strain. A stress-strain curve was then plotted using the experimental data 
(load versus deformation) and the compressive modulus and strength was 
recorded for each specimen, with the stiffness being measured as the slope of 
the linear portion of the curve. 
Push out test 
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3.2.7 Histological Analysis 
The specimens were removed and stored in neutral buffered formalin 
(NBF) 4% and were dehydrated in ascending series of alcohol rinses and 
embedded using a process that produced ground sections with the glycol 
metacrylate resin.  Once polymerized, the block was trimmed to remove excess 
plastic with an industrial vertical band saw and cut along its long axis with a 
diamond band saw (EXAKT standard saw). Ground polished sections of 10 
µm thickness were made using the EXAKT micro grinder system (EXAKT 
Technologies, Inc., Oklahoma City, OK) and were subsequently stained with 
Goldner’s trichrome to identify new bone formation. Three defects per group 
were used at each time point per analysis.  
3.2.8 Histomorphometric Analysis 
Images of stained sections were taken with an Olympus SZX12 
microscope connected to a CCD camera and measured using Bioquant Image 
Analysis® software (Nashville, TN, USA). The region of interest (ROI) was 
defined as area containing tissue within the defect site reaching from the 
periphery of the host bone. New bone was quantified by selecting a fixed 
threshold for positive stain pixels (black for Von Kossa). Percentage of bone 





3.2.9 Mineral Apposition Rate (MAR) 
Prior to the animal sacrifice, fluorochrome markers alizarin red and 
calcein green were administered into the rabbits at a time interval of 10 days. 
Using unstained slides under fluorescence, high magnification (20x) images 
were obtained for regenerated bone in the defect site using an epifluorescence 
microscope (model BX51; Olympus). Up to 10 fields of view were taken for 
each specimen. Two images were taken at each site using a green and a red 
filter. Images were then merged with Adobe Photoshop and the inter-label 
distances were measured using Bioquant Image Analysis® software 
(Nashville, TN, USA) (Figure 3.3). The distances were taken from the center of 
the first label to the center of the second label perpendicular to the labelled 
surfaces. Mineral apposition rate was calculated using the formula below: 
 
 




3.2.10 Statistical Analysis  
All values in this study were presented as mean values ± standard 
deviation (SD). Data analyses and comparisons were performed using 




Throughout the surgery and post implantation period, rabbits showed no 
signs of infections and were sacrificed at respective time points. Implanted 
scaffolds remained in position throughout the entire study. Upon explantation 
after 12 weeks, all defects created were completely filled. Samples felt hard 
and vessels could be observed in all specimens.  
3.3.1 Scaffolds characterisations 






A 74.9 ± 1.7 500 ± 73 0.163 ± 0.02 
B 86.7 ± 0.2 723 ± 92 0.143 ± 0.003 
+
TCP particles appeared as bright white particles relative to grey PCL as 
shown in µ-CT images (Figure 3.1). They were shown to be evenly distributed 
throughout the scaffold.  The fused deposition modelled scaffolds were fully 
Values obtained from manufacturer. P < 0.05 was observed for all parameters  




interconnected and highly porous. (Group A: 74.9 ± 1.7%, Group B: 86.7 ± 
0.2%) The pore size distribution is relatively consistent from the small 
standard deviation. The pore size of Group B was 36.9 – 42.3% higher than 
Group A.  
3.3.2 µ-CT analysis 
   
Figure 3.4: Representative µ-CT images of explants specimens with PCL-TCP 
scaffold of (A) 75% porosity (B) 85% porosity (blue: scaffold, yellow: new bone 
growth and beige: calvaria bone) 
 
  
Figure 3.5: Percentage BV/TV in PCL-TCP scaffolds by µ-CT with varying 




Before analysis of specimens, calibration was done on rabbit calvarial 
bone and scaffolds which served as a benchmark for detecting and to 
distinguish various components present in specimens (Figure 3.4). Bone 
volume (BV) here refers to the amount of new bone growth detected at defect 
site. Total volume (TV) is total volume available for growth at the defect site. 
%BV/TV was observed to increase from the start to 8 weeks and stabilised 
thereafter. There were no significant differences between Group A and B 
throughout the experiment (Figure 3.5).     
 
Figure 3.6: Scaffold volumes with varying porosities over a time period of 24 
weeks. 
Scaffold degradation in rabbit model seemed to follow a power law 
relationship, regardless of porosity (Figure 3.6). However, there is an 
additional constant which indicates that scaffold volume will fall to a specific 
volume after prolonged periods of scaffold implantation. Scaffolds were 
observed to degrade gradually throughout the study. At 24 weeks, scaffolds 
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with both porosities had volumes that closely matched each other (Group A: 
8.34 ± 0.7mm3; Group B: 7.5 ± 0.25mm3).   
 
Figure 3.7: Percentage of PCL-TCP scaffolds volume loss with varying 
porosities from 2 to 24 weeks of implantation 
 
Figure 3.7 indicates that 50% scaffold loss was achieved at different time 
points for both groups. Group B scaffolds reported 50% degradation at around 
6 weeks. This was faster than Group A scaffolds that demonstrated 50% 
scaffold loss at around 10 weeks. Between 12 to 24 weeks, degradation of 







3.3.3 Compressive strength  
 
Figure 3.8: Compressive strength of PCL-TCP scaffolds with varying porosities 
from 2 to 24 weeks of implantation (* denotes p < 0.05) 
 
Compressive strength in this study was taken at 50% strain to compensate 
for the unevenness of the specimens. Compressive strength for Group B was 
significantly lower at 2 weeks than Group A. Group A scaffolds experienced a 
increase of 103% from 2 to 12 weeks and Group B scaffolds peaked at 8 weeks 
and decreased after that (Figure 3.8). Porosity variations did not have a 







3.3.4 Push Out test 
 
Figure 3.9: Shear strength of PCL-TCP scaffolds with varying porosities from 2 
to 24 weeks of implantation (* denotes p < 0.05) 
 
Groups A and B showed a similar trend for shear strength at different time 
points even though the decrease in Group B compared to Group A was 
significant at 12 weeks (Figure 3.9). This suggests that the differences in 
porosity had no immediate effect on shear strength. Shear strength of both 











Figure 3.10: Representative images of ex vivo specimens at (A) 4 weeks (B) 8 
weeks stained for Goldner’s Trichome (green sections: mineralised bone; areas 
labelled ‘S’ denote PCL-TCP scaffolds) 
 
 Harvested samples were stained with Golder’s Trichome to identify new 
bone formation in the defect site. New mineralised bone (green stains) was 
detected between scaffolds rods and more evidently at later part of the study. 
No significant differences were observed between groups. Overall, the absence 
of fibrous encapsulation was an indication that PCL-TCP scaffolds were 
compatible with its surroundings. The non-resorbable membrane (grey lining) 
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served as an orientation due to its position as top layer in the specimens. 
Multi-nucleated giant cells were observed on the surface of scaffolds but not 
on mineralised bone.  Neovascularisation, specifically in the presence of 
vessels was also observed at the defect site.   
3.3.6 Histomorphometric Analysis 
    
Figure 3.11: Percentage BV/TV of PCL-TCP scaffolds by histomorphometry 
with varying porosities from 8 to 24 weeks of implantation 
 
New bone formation within defect site was divided by total defect area 
to obtain %BV/TV by histomorphometry (Figure 3.11). Similar trend was 
observed using µ-CT in Figure 3.5. 
Bone mineralisation rate was measured by fluorescence quantification 
from 8 to 24 weeks. The images demonstrated distinct clear labels in the defect 
sites. This was an indication that new bone formation was actively taking 
place.  Flurochrome labels for 2 and 4 weeks were spread out and diffused 




Figure 3.12: Representative image showing diffused flurochrome labels 
between 2 and 8 weeks (red label – alizarin, green label – calcein) 
 
3.3.7 Mineral Apposition Rate (MAR) 
 
Figure 3.13: Mineral Apposition Rate (MAR) of PCL-TCP scaffolds with 
varying porosities from 8 to 24 weeks of implantation 
 
There was no significant differences between MAR of Group A and Group 
B. MAR for Group A peaked at 12 weeks (1.38µm/day) and Group B at 8 
weeks (1.52µm/day). Both groups exhibited a reduction in MAR to 0.92 - 0.97 





Pore size and porosities serve as important material properties which 
enable comparison between different scaffolds in bone regenerative and 
scaffold degradation abilities. Pore size is important in bone regeneration as 
they act as channels for cells and vessels to enter matrix for effective bone 
formation. It also directly linked to mechanical strength of the scaffold. This is 
especially vital for implantation to load bearing sites. Here, scaffolds of 75% 
and 85% were chosen as previous studies by our group demonstrated 
promising results with porosities between 70 – 90% and also to determine 
whether there are any differences in bone regeneration in vivo with the 
porosity difference. 
  Current literature reported conflicting results ranging from increased 
bone regeneration for scaffolds with higher porosity (Ikeda et al., 2009; Kuhne 
et al., 1994; Schliephake et al., 1991); lower bone growth with increased 
porosity (Eggli et al., 1988; Flautre et al., 2001) and limited or no effects at all. 
(Kasten et al., 2008; Roosa et al., 2009; Takahashi and Tabata, 2004). This 
propels our team to investigate the effects of pore size and porosity on 
previously researched PCL-TCP scaffolds that has proved its effectiveness in 
bone regeneration through numerous studies (Yeo et al., 2008a; Yeo et al., 
2009b). The objective of this study was to compare the effects of two different 
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porosities of scaffolds on bone growth and scaffold degradation in a rabbit 
calvarial defect.  
µ-CT characterisation of native scaffolds indicated that Group A (75% 
porosity) had smaller pore sizes and larger rod diameters than Group B (85% 
porosity). All the parameters indicated in Table 1 are closely related to 
porosity. It has been shown previously that when the diameter of rods/fibers is 
comparable or smaller than cells, quality and quantity of cellular attachment 
will be reduced (Karageorgiou and Kaplan, 2005; Takahashi and Tabata, 2004). 
The rods diameters’ of PCL-TCP scaffolds used in this study are about 100x 
larger than size of cells which are about 10µm. µ-CT analysis has been used 
widely to determine the extent of bone regeneration in BTE. This is mainly 
because it is a non-destructive and fast technique. It also allowed us to 
distinguish between scaffold, new bone formation and surrounding calvaria 
bone within the specimen (Figure 3.6). The % BV/TV was found to increase by 
68.6 - 100.6% from 2 to 8 weeks for both groups. Immediately after 
implantation, increased blood flow at defect site, as indicated by the presence 
of blood vessels in histology, initiated the cascade of wound healing and tissue 
ingrowth. Bone formation at defect site was clearly detected on µ-CT images 
(Figure 3.4).  After 8 weeks of implantation, bone growth for all groups 
generally seems to have stabilized. The reduction of growth rate across all 
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groups suggests that bulk of bone remodelling is taking place (Yeo et al., 
2009b).  
Following µ-CT analysis, the mechanical properties of scaffolds were 
analysed. An implant can collapse if bone fails to infiltrate enough before 
scaffold is resorbed considerably. However, scaffold degradation profile is 
often neglected in previous studies as the emphasis is usually on bone 
regeneration (Aronin et al., 2009; Heo et al., 2009). In this study, overall 
degradation profile of PCL-TCP scaffolds in a rabbit model was mapped out 
and analysed. We showed that PCL-TCP scaffolds degraded according to the 
power law relationship described below:  
         (3.1) 
Where y refers to current scaffold volume 
x denotes time after implantation in weeks  
C and n refer to constants depending on scaffold properties and environment. 
d denotes scaffold volume that will remain after prolonged periods of 
implantation 
 
This equation allowed us to predict remaining scaffold volume (mm3) at a 
specific time, thus enabling unobstructed bone growth by using an 
appropriately selected scaffold. Group B (85% porosity) scaffolds broke down 
more rapidly than Group A (75% porosity) before 12 weeks. After which, the 
volume of scaffold remained constant. Here, degradation of PCL-TCP 
scaffolds followed the degradation profile of PCL which degraded in two 
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stages namely: 1) surface erosion 2) bulk degradation. The first step is the non 
enzymatic, random hydrolytic ester cleavage which is triggered automatically 
by carboxyl end groups of the polymer chain. Chemical structure and 
molecular weight of polymer will affect the duration of the first step of 
degradation. When the molecular weight of polymer decreased to about 5000, 
second step of degradation will commence. The rate of chain scission and 
weight of polymer will decrease as a result of the formation and removal of 
short chains of oligomers from the scaffold matrix. Fragmentation of polymer 
precedes the absorption and digestion of polymer particles by phagocytes or 
enzymes (C.G Pitt, 1981; Vert, 2002). TCP particles in PCL scaffolds are more 
hydrophilic thus preferentially eroded when implanted. This causes TCP 
particles to dislodge and increases surface area of PCL thereby accelerating 
surface erosion (Lam et al., 2009; Yeo et al., 2010). Further analysis of previous 
degradation profile of alkaline treated PCL-TCP scaffolds also pointed to 
power law relationships, but to a lesser extent (lower R2 value). This can be 
explained by formation of pits on scaffold surface after alkaline treatment 
leading to a faster surface erosion process (Yeo et al., 2009b). Here, first stage 
of degradation can be inferred to occur throughout the entire experiment. 
Thus, degradation profile here (Equation 3.1) is only valid during the surface 
erosion of PCL-TCP scaffolds.  Bulk degradation, which is a slower process 
will follow thereafter, may have a degradation profile which is completely 
different from Equation 3.1. 
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Compressive strength of specimens can be regarded as a composite 
which is guided by the rules of mixture or Voigt model (Lakes, 2007).  
     (3.2) 
Where σ refer to compressive strength, f refers to volume fraction,  denotes 
total strength, subscript S refers to scaffold component and subscript B refers 
to bone component. Compressive strength is heavily influenced by the amount 
of bone in the defect site. This is evident in the close resemblance in the 
compressive strength and bone volume charts. Structural integrity of 
specimens was evaluated by measuring compressive and interfacial shear 
strength.  There was no significant differences between Groups A and B, 
except at 2 weeks. The initial lower strength for Group B is probably due to 
low compressive strength of scaffold as bone in-growth is still insufficient to 
influence overall strength. Strength of bone  is much larger than 
scaffold . Thus, the dominant factor in total strength  changed from 
scaffold strength to new bone strength during the experiment. Low volume 
fraction of scaffolds ) (high porosities for Group A and B) also 
contribute to the above.  
Push out tests, which have been used widely to determine the 
mechanical strength of implants at the interfaces in animal studies (Müller et 
al., 2006; Sawyer et al., 2009). In this study, emphasis is placed on shear 
strength between scaffolds in defect site and surrounding calvaria walls. 
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Increase from 2 to 4 weeks has been discussed previously. There were no 
significant differences between Group A and B except at 12 weeks. The initial 
increase before 4 weeks can be attributed to the bone growth starting from the 
calvaria wall surrounding defect. After that, shear strength stabilised probably 
due to sufficient bone has already infiltrated defect site at 4 weeks and new 
bone continues its growing path into the centre of scaffolds. The above is 
supported by %BV/TV values and histology images.  
Histological analyses at various time points affirmed the findings from 
µ-CT in that bone has penetrated scaffold voids more evidently at a later stage. 
Adipose tissue was also residing alongside with bone. There was no evidence 
of fibrous encapsulation of scaffolds in all specimens observed. This confirmed 
PCL-TCP biocompatibility in an in vivo which attests to previous research 
findings (Lam et al., 2009; Rai et al., 2007; Yeo et al., 2009b). Multi-nucleated 
giant cells were observed to be only on the surface of scaffolds rods. Thus, they 
were probably involved in the breaking down of PCL-TCP scaffolds and not 
the newly formed bone. Vascularisation observed within regenerated defect 
sites for both scaffolds indicate that vessels were able to infiltrate scaffolds 
with pore sizes above 500µm, which is agreement with studies discussed 
previously (El-Ghannam, 2004). 
Histomorphometric analyses largely corroborated with µ-CT findings 
in terms of bone volume. However, two and four week’s data were omitted 
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due to failure in bone detection. Bone was actively forming and new woven 
bone does not have an organised structure that may have contributed to the 
diffused flurochrome labelling, which negates any measurements. Notably, 
MAR was able to provide us with bone growth rate in a lamellar fashion using 
distances between inter-label distances. Generally, MAR seems to be declining 
from 8 to 24 weeks and this might be due to remodelling that reduced 
osteoblastic activity (Yeo et al., 2009b). This may be attributed to the 
regeneration of cancellous calavria bone within defects at 12 weeks.  Empty 
pores within new bone growth evident in histology images can thus be 
considered as trabecular structure of rabbit calavria. 
Previous studies in rabbits had resulted in similar findings compared to 
our current study. In an eight week study by Fisher et al, implantation of 
poly(propylene fumarate) scaffolds subcutaneously in rabbit calvaria did not 
indicate any significant differences when pore sizes (300 – 500µm and 600 - 
800µm) and porosities (57 – 75%) were varied (Fisher et al., 2002).  Identical 
findings were obtained when nitinol implants of varying pore sizes (179, 218 
and 353 µm) and porosities (54, 51, 43%) were implanted into rabbits for 6 
weeks (Ayers et al., 1999). Minor differences between scaffold groups may 
have diminished its effects on bone regeneration and scaffold degradation in 
this study.  Only two groups of untreated scaffolds were presented here as a 
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concurrent study with alkaline treated PCL-TCP scaffolds which has been 
published elsewhere (Yeo et al., 2010; Yeo et al., 2009b).  
In the above studies, including our current work, the thickness of the 
specimen was in the same order of magnitude as the implant diameter. One 
limitation in adopting rabbit calvarial defect model lies in the thickness of 
implants must conform to that of calvaria. Here, PCL-TCP scaffolds has a 
thickness of 2mm. The impact of porosity variations on bone regeneration and 
scaffold degradation was reduced as cellular and vascular infiltration is better 
in thin models (Ayers et al., 1999). To address this problem, larger animal 
models which enable thicker scaffold implants should be used for studies with 
porosity and pore size as variables. This is in agreement with the hypothesis 
that there should be a critical thickness to pore size ratio that will have a 
significant impact on bone regeneration (Ayers et al., 1999).  
 
3.5 CONCLUSIONS 
This study aimed to investigate the effects of porosity and pore sizes of 
PCL-TCP scaffolds on bone regeneration, scaffold degradation and mechanical 
properties in rabbit calvarial defects over 24 weeks. Results indicated that 
there were considerable bone growth and scaffold degradation especially at 
the later stages of the study. Bone remodelling has already taken place at 24 
weeks evidently from histology images but shear strength of implants were 
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not compromised. Absence of inflammatory cells affirmed previous findings 
that PCL-TCP scaffolds are biocompatible. Histomorphometric analysis 
affirmed µ-CT and mechanical test results. In all, pore size and porosities have 
negligible effects on bone regeneration, scaffold degradation and structural 
















CHAPTER 4: PRELIMINARY EVALUATION OF PCL-TCP 
SCAFFOLDS AS CO-DELIVERY SYSTEMS FOR HEPARIN 
AND BMP-2 IN VITRO 
 
4.1 INTRODUCTION   
In Chapter 3, ability of PCL-TCP scaffolds as a biomaterial upon 
implantation into rabbit calvarial has been proven. However, acellular 
scaffolds may not be the best option when treating large defects. Initial rigidity 
of scaffold may not be sufficient to protect underlying brain unless new bone 
formation is accelerated (Salyer et al., 1995). Thus, the use of growth factors eg 
bone morphogenetic protein-2 (BMP-2) in this chapter come into play.  
Documentations of the effectiveness of BMPs can be traced back to the 
1960s. Urist found that BMPs are the proteins involved in bone healing. 
Subsequently, BMP-2 has demonstrated its powerful osteoinductive abilities in 
various studies.  BMP-2 belongs to the superfamily of Transforming growth 
factor (TGF)-β. BMPs ha s been shown to pla y an active role in cellular 
regulation and function in bone function and repair. Furthermore, BMP-2 is 
approved by FDA for use in fracture and spinal fusion applications (Jones et 
al., 2006; Mont et al., 2004). 
However, BMP-2 has short half life in vivo (Yamamoto et al., 2003). 
Sustained release of BMP-2 has not been achieved at defect sites, thus 
researchers turned to the usage of high and multiple doses (Jones et al., 2006). 
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This resulted in adverse effects including bone growth away from the defect 
site (Lieberman et al., 2002; Valentin-Opran et al., 2002) and high cost of BMP-2 
incurred for repeat administrations.  Therefore, it is essential to develop a 
system where the delivery of bioactive BMP-2 to the defect site is both 
localised and sustained.  
PCL-TCP have been shown to demonstrate excellent properties as bone 
void fillers in chapter 3 and in previous studies (Lam et al., 2007; Rai et al., 
2007; Yeo et al., 2009a). Notably, PCL-TCP scaffolds had also been investigated 
for its delivery properties with BMP-2 in combination with fibrin sealant. PCL-
TCP scaffolds when loaded with 20µg/ml of BMP-2 exhibited a triphasic 
release profile, that was sustained. BMP-2 retained its bioactivity even after 21 
days. (Rai et al., 2005b).  
Heparin is a sulphated polysaccharide which belongs to 
glycosaminoglycan (GAG) family. It has been demonstrated to have an affinity 
for growth factors namely BMP-2, FGF and VEGF (Steffens et al., 2004; 
Wissink et al., 2000). Heparin binds to BMP-2 directly through the N-terminal 
region of the mature polypeptide (Chung et al., 2007). BMP-2 bioactivity is 
prolonged as a result.   The bioactivity and half-life of BMP-2 in culture 
medium were increased by 20-fold when heparin was present (Zhao et al., 
2006).  In view of the above, a co-delivery system of heparin and BMP-2 with 
PCL-TCP scaffolds was proposed in this study. The effects of heparin and 
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BMP-2 on pig osteoblasts were first investigated for increased osteogenic 
differentiation. The concentrations of heparin and BMP-2 with heightened 
ALP activities were chosen for subsequent analysis. Following that, BMP-2 
delivery profile in PBS buffer was mapped out and evaluated.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Porcine osteoblasts culture 
Porcine bone chips were obtained from pigs following their sacrifice after 
surgical procedures as per ethical code.  Bone chips (~2-3mm thickness) were 
harvested from the mandible and incubated in a solution of PBS (containing 
antibiotics/antimycotic) for transport back to the laboratory.  They were then 
vortexed in PBS (containing antibiotics/antimycotic) until the hematopoeitic 
tissue was removed from the bone chips.  The bone chips were dissected into 
pieces of 2mm x 2mm. Bone chips were then immersed in Alpha MEM media 
supplemented with 10% FBS (Hyclone, USA) and 1% PS at 37°C and 5% CO2
4.2.2 Cell culture and BMP-2 treatment 
, 
untouched for 1 week, before changing media.  Medium was replaced every 3 
days and cells were passaged when they are 70% confluent.  
Cells at passages 3-5 were used throughout the experiment. Pig osteoblasts 
(20000 cells/cm2) were plated in 24-well plates. Cells were inoculated in 3 ml of 
osteogenic medium (Alpha MEM, 10% FBS (Hyclone, USA), 1% PS, 1µM Dex, 
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0.05mM absorbic acid and 10mM glycerol-2-phosphate) for 24 hrs. Following 
that, medium was changed and replenished with treatment medium 
containing varying concentrations of BMP-2 (R&D Systems, USA). 30µl of 
BMP-2 (10, 100, 300 and 1000ng/ml) was added to the treatment medium and 
cells were cultured for 3 days. Cells were lysed by rinsing with 1ml PBS/1mM 
PMSF twice on a rotary shaker first. After addition of RIPA buffer (1% Triton 
X-100, 150mM NaCl, 10mM Tris pH7.4, 2mM EDTA, 0.5% Igepal, 0.1% SDS) 
and 1% of protease inhibitor(Calibiochem, Germany), cells were scraped using 
pipette tips and placed on rotary shaker (100rpm) at 4°C for 15 minutes. 
Suspensions were then centrifuged down at 11,000rpm at 4°C for 10 minutes 
and supernatants were extracted for further analysis. All experiments were 
carried out in triplicates.  
4.2.3 Heparin and BMP-2 treatment  
After the optimal concentration of BMP-2 with heightened ALP activity 
was determined, concentrations of heparin (10, 100, 1000ng/ml) was in turn 
varied. 30µl of heparin was incubated with 10µl of BMP-2 (10µg/ml) for 20 
minutes. 1ml of PBS was resuspended with the mixture and added to each 
well containing the pig osteoblasts.  
4.2.4 Protein determination  
The amount of proteins in lysed cells was determined using BCA protein 
assay kit (Thermo Scientific, USA). 90µl of mixed reagent (A:B = 50:1) was 
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added to 10µl of samples in 96-well plates. This was followed by incubation at 
37°C for 30 minutes. Protein concentration was determined 
spectrophotometrically at 595nm using multilabel counter.  
4.2.5 Alkaline phosphatase activity 
20µl of the lysed samples with protein concentrations of 20µg/ml were 
placed into each well. The positive well consists of 1µl of Calf Intestinal 
Phosphatase (Research Biolabs, England) and 19µl of RIPA buffer. 40µl of 
assay buffer (1x pNPP buffer: Invitrogen, USA) was added to each well. After 
incubation at 37°C for 60 minutes, samples were read at 405nm for 
measurement of ALP activity.  
4.2.6 Western blot 
Lysates (12 µg of proteins) were separated on 10% (w/v) SDS–
polyacrylamide gels and electroblotted onto nitrocellulose membranes. 
Overnight incubation with primary antibodies (p-SMAD 1/5/8, Cell Signalling, 
USA; Smad1/5/8, Santa Cruz, USA) was carried out at 4°C, followed by 
secondary antibodies for 3 h at room temperature. Membranes were then 
exposed to X-ray films for band detection.  
4.2.7 Alizarin red staining 
Confluent cells on well plates were rinsed 3x with PBS. They were then 
fixed in 4% formaldehyde for 10 mins and rinsed 3x with DI water. Alizarin 
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red solution (13.7g/L) was added to cells and incubated for 30mins on shaker. 
Cells were left at room temperature to dry for 2 days.  
4.2.8 Release profile studies  
Pig osteoblasts, with optimal concentrations of 30µl of BMP-2 and equal 
volumes of heparin, mixed with fibrin glue (Tisseel kit, Baxter, USA) were 
seeded onto scaffolds directly in 24 wells plates. After 1 hr of incubation at 
37°C, scaffolds were flipped over and resuspensed to ensure complete 
solidifying of mixture. After the second incubation period, 2ml of PBS was 
added to individual wells. PBS was replaced at selected intervals: 2h, Day 1, 4, 
7, 14, 21, 28 and analysed for BMP-2 and total protein release.  
4.2.9 BMP-2 Release 
BMP-2 release was assessed using an ELISA kit (Quantikine, R&D Systems, 
USA). Supernatants were collected and frozen down to -20°C immediately. 
Prior to analysis, they are thawed and 50µl of samples were assessed for BMP-
2 concentration according to manufacturer instructions.  
4.2.10 Statistical Analysis  
All values in this study were presented as mean values ± standard 
deviation (SD) of the mean. Data analyses and comparisons were performed 
using Student’s paired t-test (Microsoft Excel). P-values of < 0.05 were 





4.3.1 Optimal BMP-2 concentration 
 
Figure 4.1: Alkaline phosphatase activity per mg protein of cells at different 
BMP-2 concentrations (* denotes p < 0.05) 
 
Alkaline phosphatase (ALP) activity was monitored as it is a standard 
early marker for osteogenesis. The results showed increased ALP activity in 
pig osteoblasts when treated with 100, 300 and 1000ng/ml of BMP-2(Figure 
4.1). ALP activity was highest at 1000 ng/ml of BMP-2. However, optimal 
concentration was chosen to be 100 ng/ml due to high cost of BMP-2 and 







4.3.2 Western blot analysis 
 
Figure 4.2: Western blot for pig osteoblasts treated with 100ng/ml BMP-2 at 
different treatment times. (top - phosphorylated SMAD 1/5/8 and bottom – 
Total SMAD 1/5/8) 
 
In the presence of BMP-2, total SMAD 1/5/8 was converted to p-SMAD 
1/5/8, according to the TGF-β signaling pathway as described in Chapter 2. Fig 
4.2 indicates a higher expression for both SMAD and p-SMAD after 24 hours 
of BMP-2 treatment.  The total SMAD expression was decreased significantly 








4.3.3 Alizarin red staining 
 
Figure 4.3: Alizarin red staining for pig osteoblasts with and without BMP-2 
(control) treatment for 3 weeks. 
Alizarin red staining was used to detect calcium deposition in cells. BMP-2 
was shown to induce mineralization when added to C2C12 cells after 7 days 
(Bessa et al., 2009). Slightly darker staining was observed for BMP-2 treated 
pig osteoblasts relative to controls. This indicates increased mineralization of 
osteoblasts induced by BMP-2.  
4.3.4 Optimal heparin concentration 
 
Figure 4.4: Alkaline phosphatase activity per unit protein of cells at different 




Heparin had been shown to have a potentiating and stabilizing effect on 
BMP-2. ALP/protein activity of pig osteoblasts treated with 100 ng/ml of BMP-
2 was significantly higher than untreated ones. At 300ng/ml of heparin, ALP 
activity was higher than at other concentrations (13.7-33.5%). Thus, it was 
chosen as optimal concentration for further analyses.  
4.3.5 Protein release profile 
 
Figure 4.5: Amount of total protein release at various time points (Group A: 
PCL-TCP scaffolds loaded with PBS. Group B: PCL-TCP scaffolds loaded with 
100ng/ml BMP-2. Group C: PCL-TCP scaffolds loaded with 300ng/ml of 
heparin. Group D: PCL-TCP scaffolds loaded with 300ng/ml of heparin and 
100ng/ml of BMP-2) 
  
The general trend of protein release was a biphasic release for all groups 
except heparin.  High level of proteins was released at 2hr (0.55 – 0.74mg/ml) 
and day 14 (0.52 – 0.66mg/ml). Protein release from Group C exhibited a 
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different release profile relative to other groups where the concentration was 
0.54mg/ml at 2hr and decreased throughout the study.  
4.3.6 BMP-2 release profile 
 
Figure 4.6: Amount of BMP-2 release at various time points. (Group A: PCL-
TCP scaffolds loaded with PBS. Group B: PCL-TCP scaffolds loaded with 
100ng/ml BMP-2. Group C: PCL-TCP scaffolds loaded with 300ng/ml of 
heparin. Group D: PCL-TCP scaffolds loaded with 300ng/ml of heparin and 
100ng/ml of BMP-2) Group A and C showed no release of BMP-2 at all time 
points. 
 
The concentration of BMP-2 release in PBS was determined using 
ELISA kit. Group B demonstrated a biphasic release with heightened release at 
2hr and day 14. However, Group D did not exhibit a significant BMP-2 release 






4.3.7 ALP bioactivity of eluted BMP-2 
 
Figure 4.7: Bioactivity of eluted BMP-2 at different time points (Group A: PCL-
TCP scaffolds loaded with PBS. Group B: PCL-TCP scaffolds loaded with 
100ng/ml BMP-2. Group C: PCL-TCP scaffolds loaded with 300ng/ml of 
heparin. Group D: PCL-TCP scaffolds loaded with 300ng/ml of heparin and 
100ng/ml of BMP-2) 
 
Generally, there were no significant differences between all groups at 
various time points. Group B and D exhibited higher ALP activity at Day 1 
and 4 compared to other groups (25.5 – 66.5%). ALP activity range of Group A 




As discussed previously, there are numerous studies on the delivery of 
BMP-2 using a 3D matrix (Hosseinkhani et al., 2007; Kempen et al., 2008; Ruhé 
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et al., 2005). Problems like initial bursts upon implantation and bone growth 
away from defect sites indicate that BMP-2 delivery is far from ideal. Our 
group proposes a new co-delivery method of using heparin to effectively 
deliver BMP-2 to the defect sites. Heparin has shown to potentiate, sustain and 
stimulate BMP-2 through binding to its N-terminal (Zhao et al., 2006). Here, 
BMP-2 and heparin were seeded onto biodegradable PCL-TCP scaffolds using 
Tisseel fibrin sealant.  
This study focused on the effects of heparin and BMP-2 on pig osteoblasts 
and their release profile over 4 weeks when seeded in PCL-TCP scaffolds 
using fibrin sealant. Pig osteoblasts obtained from mandible explants were 
used in this experiment. This is in line with our next step to implant PCL-TCP 
scaffolds loaded with heparin and BMP-2 into pig mandible defects. Thus, this 
will paint a more accurate picture on the effects of heparin and BMP-2 on pig 
osteoblasts upon implantation. The bioactivity of BMP-2 can be verified by the 
responsiveness of pig osteoblasts through ALP activity. It has been used 
widely as a biochemical marker for osteoblast differentiation (Cremers et al., 
2008; Katagiri et al., 1994). Pig osteoblasts displayed heightened ALP activity 
when subjected to 100, 300 and 1000ng/ml of BMP-2 (Figure 4.1). Increased 
ALP activity on C2C12 cells in demineralised bone matrix had been proven by 
(Lin et al.). Similar effects have also been reported in another study (Zhao et 
al., 2006). Highest ALP activity was obtained at 1000ng/ml. However, 
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100ng/ml was chosen primarily because of high cost of BMP-2 involved. 
Another reason is that ALP activity of 300ng/ml seemed to have no significant 
difference compared to 100ng/ml.  
Western blot and alizarin red staining were then performed to verify 
translated protein expression and mineralisation of pig osteoblasts by BMP-2 
treatment. According to cell signalling pathway, total SMADs are present in all 
cells and they will be converted to p-SMAD in the presence of BMP-2. A 
higher expression of p-SMAD is detected at 24h compared to 2 and 48h. This is 
in agreement with the cell signalling pathway. This was affirmed by previous 
findings by our group when BMP-2 treatment times on C2C12 cells were 
varied (data not shown). However in Figure 4.2, total SMAD were not fully 
expressed at 2 and 48h. This deviation from signalling pathway might be due 
to technical error during blotting or reduced bioactivity of primary antibodies. 
Repeated freeze thaw activity and prolonged period of storage may result in 
instability of its properties. Mineralisation of treated cells at 3 weeks was 
detected by alizarin red staining. BMP-2 treated cells displayed a darker shade 
of red which is in agreement with western blot findings. BMP-2 used in this 
study resulted in increased osteoblast differentiation, induced p-SMAD 
expression and mineralisation in pig osteoblasts.  
In Figure 4.4, optimal concentration ratio of BMP-2 to heparin was 
found to be 1:3. Similar study conducted on C2C12 cells with ratio of 1:5 
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demonstrated that heparin enhance osteoblast differentiation. Concentration 
obtained here indicates that heparin has a positive effect on BMP-2 activity. 
More testings on animal studies is needed to confirm the ratio.  
Method of introducing heparin to BMP-2 may influence their interactions, 
resulting in varied effects in bone regeneration. Direct addition of heparin to 
BMP-2 (Zhao et al., 2006), crosslinking of heparin to demineralised bone 
matrix (Lin et al., 2008) and conjugation of heparin to PLGA scaffolds (Jeon et 
al., 2007) were some of the methods that was previously used and with good 
results. Here, BMP-2 was allowed to react with heparin first during incubation 
before mixing with medium and applying to cells. This allows sufficient time 
for N terminal bonds to occur and prevent other reactions that may take place 
preferentially. It can also simulate conditions whereby heparin is incorporated 
in PCL-TCP scaffolds.   
Fibrin sealant is derived from blood clots and has been used effectively 
for healing of critical sized bone defects and non-unions in cats, dogs and rats 
(Schmoekel et al., 2005). It has also been established as an effective method to 
sustain BMP-2 diffusion. This is verified when fibrin is used in collagen 
sponge for BMP-2 delivery in a rat spinal model. It has shown successfully to 
control bone growth in undesirable areas such as nerve tissues (Patel et al., 




Protein release in PBS can be attributed to fibrin and BMP-2 eluted from 
scaffolds. Fibrin release is dominant here as concentration of BMP-2 is 
relatively lower at 100ng/ml (Figure 4.6). Biphasic protein release was evident 
in Group A, B and D. Profile was similar to BMP-2 released for Group B and D. 
Initial burst at 2h and Day 1 was mainly due to release of fibrin sealant and 
uncrosslinked fibrin on the scaffold surface. Between day 4 to 7, BMP-2 was 
locked in PCL-TCP scaffolds by fibrin sealant. At this time, scaffolds were 
bound to the surface of well plate. Subsequent release of BMP-2 at Day 14 can 
be attributed to the disintegration of fibrin within scaffolds whereby BMP-2 
was released concurrently (Figure 4.6). Fibrin loaded scaffolds were also 
observed to dislodge from the well plates. Release of BMP-2 after Day 14 can 
be attributed to the release of TCP which has the ability to form intermolecular 
bonds with BMP-2. Previous studies confirmed the findings (Rai et al., 2005b; 
Wei et al., 2004).  
There was a huge difference between Group C release profile relative to 
the rest. Heparin seemed to react with fibrin sealant at the start of experiment 
and thus resulting in a constant decrease in protein throughout the 
experiment. Performance of fibrin in the presence of heparin has been 
elucidated by Marx et al. Heparin did not have any effect on clotting time but 
bonding strength was decreased by 20% (Marx and Mou, 2002). Here, Group 
C’s protein release profile exhibited an initial burst and declined thereafter. It 
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is well known that heparin prevents the formation of fibrin clot by a series of 
coagulation cascade activities. Even though different reaction has occurred 
when heparin reacts with fibrin sealant causing degradation profile to differ, 
clot formation and mechanical properties still remain intact. More in depth 
characterisations are needed to determine the cause of this phenomenon. ALP 
activity of the eluted BMP-2 did not exhibit any significant differences from 
controls. This is to be expected from the low concentration of BMP-2 eluted 
(Figure 4.6). Any concentration that is lower than 10ng/ml as depicted in 
Figure 4.1 will have negligible effects relative to controls. 
 
4.5 CONCLUSIONS 
Heparin and BMP-2 has been investigated previously as supplementary 
factor in the realm of bone regeneration. Here, heparin incubated with BMP-2 
demonstrated higher ALP activity in pig osteoblasts than BMP-2 alone. The 
bioactivity of BMP-2 was also verified at different time points. Interestingly, 
BMP-2 in the presence of heparin when loaded on PCL-TCP scaffolds did not 
showed a sustained release as hypothesized. More analysis is needed to 
confirm the hypothesis. Further studies should focus on the controlled release 





CHAPTER 5: FINAL RECOMMENDATIONS 
5.1 Effects of porosities of PCL-TCP scaffolds on in vivo bone 
regeneration.  
This particular chapter has its emphasis on two issues namely surface 
modification and porosity of acellular PCL-TCP scaffolds where the latter is 
the focus here. Thickness to pore size ratio of scaffolds was not studied in this 
study and can be an interesting research area to look at. A micro pig model 
will be appropriate for this study whereby thickness of the scaffolds can be 
varied. Critical sized circular defect can be used again which allow for more 
accurate determination of region of interest. Micro CT, histology and 
mechanical testing should be conducted at 3 and 6 months to determine extent 
of bone formation, cellular interactions and mechanical properties can be 
evaluated. Mechanical properties can provide us with information on 
structural integrity of specimens at that particular point. Similarly, 
degradation profile of scaffolds can be mapped using data from Micro CT. 
This will be more representative as it is conducted on a larger animal model.  
 
5.2 Preliminary in vitro evaluation of PCL-TCP scaffolds as co-delivery 
systems for heparin and BMP-2 
Optimal concentrations and ratio of BMP-2 and heparin have been 
determined in Chapter 4. Release of BMP-2 is inconclusive which is mainly 
due to low concentration of BMP-2 used. Separate release study with a higher 
69 
 
concentration of BMP-2 and heparin whist maintaining the optimal ratio (1:3) 
can be conducted. In fact, heparin release using alexa fluro has been conducted 
concurrently in this study.  Even though lowest detectable concentration stood 
at 24ng/ml, no heparin was detected at 485nm. There is a possible reaction that 
occurred between heparin and fibrin sealant as described in Chapter 4. 
Heparin can also be radiolabelled and release can be tracked using suitable 
counter. Next step can be to incorporate pig osteoblast into PCL-TCP scaffolds 
with optimal ratio of heparin and BMP-2. At various time points, 
characterisation like ALP, BCA and picogreen can be conducted to determine 
their extent of differentiation, protein concentration and DNA content. 
Alizarin red staining will also be able to determine the extent of 
characterisation. Viability of cells on surface and within scaffolds can also be 
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